No Detail Found!

The Effect of Pirfenidone on Peyronie Plaques and Erectile Function in a Peyronie s Rat Model

Author(s)
Gokhan Cevik Department of Urology, Trakya University,Edirne,Turkey
Atinc Tozsin Department of Urology, Trakya University,Edirne,Turkey
Ebru Tastekin Department of Pathology, Trakya University,Edirne,Turkey
Murat Dursun Department of Urology, School of Medicine, Istanbul University,Istanbul,Turkey
Tev k Aktoz Department of Urology, Trakya University,Edirne,Turkey
Ates Kadioglu Department of Urology, School of Medicine, Istanbul University,Istanbul,Turkey
Abstract
Objective: To investigate the anti- brotic e ects of pirfenidone on Peyronie s disease in an experimental rat model with intracavernosal injection of TGF-² and whether pirfenidone improves erectile function. Study Design: Experimental study. Place and Duration of the Study: Faculty of Medical Experimental Animals and Research Laboratory, Trakya University, from January to March 2021. Methodology: In this study, 27 male Sprague Dawley rats were used, and three groups were randomly identi ed. The rats in Group 1 served as the control group. Group 2 was not treated, and Group 3 was treated with pirfenidone therapy. The rats in Group 3 were administered pirfenidone 30 mg/kg/day by oral gavage, every day for four weeks, three weeks after the start of the experiment. At the end of seven weeks, a haemodynamic study was performed with cavernosal nerve stimulation to evaluate the erectile function, the rats were sacri ced, and the penile tissues were evaluated immunohistochemically. Results: MeICP/MIBP values were found to be higher in treated rats compared to rats in the untreated group but no statistically signi cant di erence was found in MeICP/MIBP values between the control, Peyronie model, and treatment groups (p=0.25). According to the histopathological examination, the rate of brosis with H&E staining was mild (100%) in the control group, severe (100%) in the Peyronie group, and severe (87.5% severe and 12.5% moderate) in the Peyronie + treatment group. Conclusion: In the study, pirfenidone used in the treatment of Peyronie's disease had a positive e ect on erectile function, though not considered statistically signi cant. It has been shown that it has no histopathological e ect on Peyronie s plaques.
Publication Details
Page(s) 1217-1222
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 11, Year: 2023

Request the full text from PASTIC

Keywords
Erectile function, Pirfenidone, Experimental study, Anti- brotic agent, Peyronie s disease
0

Citations

0

Downloads

70

Views